StockWatch
·

Ellenbarrie Industrial Gases Ltd Q2 FY27 Results

ELLENQ2 FY27 Results
Filing
Result:Weak· Market: Crashed#Margin squeeze

Beat/Miss: Miss · Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue114.3215.8%28.2%
Total Income131.4313.5%29.1%
Expenditure83.5020.5%35.1%
PBT47.923.2%19.9%
Net Profit35.652.0%2.9%
OPM35.20%2.92pp2.34pp
NPM27.12%3.08pp8.95pp
EPS2.532.0%3.1%
View full financials

Revenue grew 28.2% YoY but adjusted PAT fell 2.9% as OPM compressed ~230bps and the effective tax rate nearly quadrupled, prompting analysts to call this a weak quarter and cut estimates/targets on gas-price cost pressure.

ELLEN · Q2 FY27 · THE VERDICT

Growth masks margin pressure

Revenue surged 28% year-over-year but net profit fell 2.9%, as consolidated EBITDA margins compressed 300 basis points. Management attributes the gap to freight costs and project staffing — both claimed temporary — but the earnings miss suggests otherwise.

06 Nov 2026 · 6 min read
Revenue

₹114.3 Cr

+28% YoY, +16% QoQ

EBITDA margin

36%

-300 bps QoQ from 39%

Net profit

₹35.6 Cr

-2.9% YoY, NPM 27.1%

Core gases margin

39%

stable, but consolidated diluted

The revenue print looks solid — 28% growth year-over-year, 16% quarter-on-quarter — but the bottom line tells a different story. Net profit fell 2.9% year-over-year despite the topline surge, and consolidated EBITDA margins compressed 300 basis points quarter-on-quarter to 36% from 39%. That gap is the quarter. Management blamed freight cost inflation and project staffing buildup, both claimed temporary. The call data suggests the margin pain runs deeper than management wants to admit.

Where the margin went

The core gases segment held its own at 39% margin (Q1: 38%), validating the underlying business. But consolidated EBITDA fell 300 bps because transportation costs spiked — diesel prices up, longer delivery routes — and employee expense jumped ₹11 million for project engineering buildup to support the BHEL contract. Management frames both as strategic investments in future execution capability. The numbers frame them as opex that offset topline gains.

EBITDA margin, %
-8.049.3226.6844.0439Q1 FY2736Q2 FY27-3Δ QoQ
Core gases margin stable at 39%; consolidated diluted by freight and staffing costs. The compression is not temporary if it persists in H2.

Claims vs. what holds up

Management's on-call assertions, graded against the delivered numbers

Revenue growth 28% YoY, 16% QoQ validates market demand and argan mix expansion.

Delivered ₹114.3 Cr (vs ₹89.2 Cr Q2 FY26, +28% YoY). H1 FY27 ₹2,130 Cr, +23% vs H1 FY26. Numbers check out.

Supported

Freight and power costs are temporary headwinds; expect normalization over next couple of quarters.

PAT declined 2.9% YoY despite 28% revenue growth. If freight/power were truly temporary, PAT should track revenue growth. The 2–3 month pass-through lag is material; recovery extends into H2, not Q3.

Overstated

Durgapur 325 TPD on-site plant commissioned in Q2 FY27, take-or-pay contract de-risks volume.

Facility operational towards end of September 2026. Q3 will be first full quarter. Contract structure verified. Milestone on track.

Supported

BHEL ₹480 Cr EPC contract awarded; validates engineering capability and coal gasification opportunity.

Contract confirmed September 2026, 8-quarter execution. Lower margins than core gases acknowledged but not quantified (single-digit to low-double digit implied). Strategic win, but margin dilution ahead.

Supported, with caveat

40%+ EBITDA margin aspiration remains on track for long-term.

Q2 delivered 36%, down 300 bps from Q1 39%. Management reframed as 'longer-term aspiration, not quarterly guarantee.' Current trajectory is compressing, not expanding.

Overstated

What changed on this call

Merchant plant timeline slipped six months. North India and West Central merchant plants (₹250 Cr capex for 450–500 TPD combined) originally guided to come online by end of FY27. Now expected H2 FY28, driven by land allotment and government approval delays. Capex amount unchanged, but incremental revenue contribution pushed out.

BHEL ₹480 Cr EPC contract awarded. Largest single project in company history. Odisha cryogenic air separation unit (1,200 TPD) execution over 8 quarters, revenue recognition Quarters 5–8 at earliest. Validates engineering capability but acknowledged to carry lower margins than core gases (single-digit to low-double digit range). Will be reported separately to allow investor comparison.

On-site plant execution validated. Durgapur 325 TPD commissioned on schedule (September 2026), 15-year take-or-pay contract. De-risks execution risk on this business model. Q3 FY27 will show first full-quarter benefit.

Capex guidance reaffirmed. ₹250 Cr FY27 and ₹200 Cr FY28 for merchant plant buildout unchanged, signaling management commitment despite timeline slip.

Street positioning — how the market reads this

The stock closed at ₹312.8, below its 20-day SMA (₹327.81) and 50-day SMA (₹339.77). From its all-time high of ₹637.7, it has fallen 50.95%. RSI sits at 44 — neutral leaning bearish. Relative to the 200-day moving average of ₹280.98, the stock holds above it, but momentum has turned decisively downward. The valuation repricing is sharp and recent.

Institutional ownership reflects selling pressure. FII holdings fell to 1.08% from 1.31% last quarter (−23 bps). Domestic institutions also trimmed, falling to 11.62% from 13.02% (−140 bps). Promoter ownership remains steady at 77.15%. The combination of a 50% drawdown from peak and continued institutional trimming suggests the market has already repriced earnings expectations downward and remains unconvinced on margin recovery near-term.

Bull-bear ledger
  • Revenue growth +28% YoY validates market demand and argan ramp

  • Durgapur 325 TPD on-site commissioned, de-risks new business model

  • ₹480 Cr BHEL EPC contract confirms engineering capability at scale

  • Core gases margin stable at 39% — underlying business remains healthy

  • PAT fell 2.9% YoY despite 28% revenue growth — cost control deteriorating

  • EBITDA margin compressed 300 bps QoQ; freight/staffing headwinds persist

  • Merchant plant delays push capex benefit out 6+ months

  • EPC contracts carry single-digit to low-double digit margins; consolidated dilution ahead

  • FII and DII both selling; institutional confidence waning

  • Stock down 50% from peak; valuation compressed sharply

Risks, ranked by how much they should concern a holder

What could go wrong, in order of impact

Margin recovery does not materialize; freight pass-through extends further

High

PAT already down year-over-year despite strong topline. If 2–3 month pass-through lag extends or customers resist price increases, margin compression persists beyond H2. Breaks confidence in guidance and jeopardizes full-year trajectory.

EPC margin dilution arrives faster than management models

High

BHEL ₹480 Cr (single-digit to low-double digit margin) begins revenue in Q3 FY28 at earliest. If execution ramps faster or incremental mix skews toward EPC, consolidated EBITDA margin falls below 40% target and persists through FY29.

Merchant plant delays extend further

Medium-high

Already slipped 6 months (FY27 end → H2 FY28) due to government approvals and land allotment. Further delays would push utilization ramp and incremental revenue beyond H2 FY28, eroding 2027 growth momentum.

Customer capex cycles deteriorate

Medium

Peak utilization (₹800 Cr revenue target) depends on pharma, steel, healthcare capex recovery. If industrial capex softens, on-site plant utilization slows and merchant plant ramp extends, delaying profit inflection.

Argan pricing softens or global supply normalizes

Medium

Argan mix uplift (10% → 16%) has driven margin benefit. Global market is tight, but if supply increases or demand softens, price support erodes and incremental margin dilutes.

What to watch next
  • 1 · Q3 FY27 margin recovery

    Will EBITDA margin expand back toward 39% as freight pass-through normalizes? This number validates or invalidates management's 'temporary headwinds' claim. If margin stays at 36% or below in Q3, the cost structure problem is structural, not cyclical.

  • 2 · Durgapur ramp and utilization

    Q3 will be first full quarter of Durgapur 325 TPD on-site operation. Track incremental revenue contribution, customer utilization trajectory, and pricing realization. Take-or-pay de-risks volume but contract terms drive economics.

  • 3 · Merchant plant government approvals

    Any update on land allotment and statutory approvals for North India and West Central plants? Reconfirmation of H2 FY28 timeline resolves delay uncertainty. Further pushouts would extend capex benefit beyond 2027 and weigh sentiment.

Ellenbarrie has delivered on its capacity strategy — Durgapur is live, BHEL ₹480 Cr contract validates engineering, and topline momentum is real at +28% year-over-year. But this quarter is steady execution, not a step-change. The margin compression and profit decline despite strong revenue growth signal that near-term opex headwinds (freight, staffing) are real and not yet normalized. Management's promise of 'temporary' cost pressure rings hollow when earnings are falling despite growth.

The stock has repriced sharply (down 50% from peak) and institutional flows are negative. At current valuations, the margin recovery story — not the revenue growth story — is what matters. If H2 FY27 delivers margin expansion and capex progress, the drawdown was an opportunity. If margins stay compressed, the sell-off has room to extend. The number to track from here is consolidated EBITDA margin. It's the deciding factor. Everything else is noise.

Informational and educational content only. Not investment advice.